Monteiro L,
Vasconcelos C, Pacheco JJ, Salazar F. Photobiomodulation laser therapy in a
Lenvatinib-related osteonecrosis of the jaw: A case report. J Clin Exp Dent.
2021;13(6):e626-9.
doi:10.4317/jced.58323
https://doi.org/10.4317/jced.58323
___________
References
|
1.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.
American Association of Oral and Maxillofacial Surgeons position paper on
medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac
Surg. 2014;72:1938-56. |
|
|
|
|
|
2.
Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, et
al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical
Practice Guideline. J Clin Oncol. 2019;37:2270-90. |
|
|
|
|
|
3.
Eguia A, Bagán-Debón L, Cardona F. Review and update on drugs related to the
development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal.
2020;25:e71-e83. |
|
|
|
|
|
4.
Vescovi P, Giovannacci I, Merigo E, Meleti M, Manfredi M, Fornaini C, et al.
Tooth extractions in high-risk patients under bisphosphonate therapy and
previously affected with osteonecrosis of the jaws: surgical protocol
supported by low-level laser therapy. J Craniofac Surg. 2015;26:696-9. |
|
|
|
|
|
5.
Fusco V, Cabras M, Erovigni F, Dell'Acqua A, Arduino PG, Pentenero M, et al.
A multicenter observational study on Medication-Related Osteonecrosis of the
Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in
North-Western Italy. Med Oral Patol Oral Cir Bucal. 2020; 24318. |
|
|
|
|
|
6.
Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-Related
Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular
Therapeutic Approaches. Stem Cells Int. 2016;2016:8768162. |
|
|
|
|
|
7.
Bagan J, Peydró A, Calvo J, Leopoldo M, Jiménez Y, Bagan L.
Medication-related osteonecrosis of the jaw associated with bisphosphonates
and denosumab in osteoporosis. Oral Dis. 2016;22:324-9. |
|
|
|
|
|
8.
Pottier C, Fresnais M, Gilon M, Jérusalem G, Longuespée R, Sounni NE.
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted
Therapy. Cancers (Basel). 2020;12:731. |
|
|
|
|
|
9.
Mauceri R, Panzarella V, Morreale I, Campisi G. Medication-related
osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral
Maxillofac Surg. 2019;48:1530-2. |
|
|
|
|
|
10.
Ferrari SM, Ruffilli I, Centanni M, Virili C, Materazzi G, Alexopoulou M, et
al. Lenvatinib in the Therapy of Aggressive Thyroid Cancer: State of the Art
and New Perspectives with Patents Recently Applied. Recent Pat Anticancer
Drug Discov. 2018;13:201-8. |
|
|
|
|
|
11.
Reed N, Glen H, Gerrard G, Good J, Lei M, Lyon AR, et al. Expert Consensus on
the Management of Adverse Events During Treatment with Lenvatinib for Thyroid
Cancer. Clin Oncol (R Coll Radiol). 2020;32:e145-e53. |
|
|
|
|
|
12.
Romeo U, Galanakis A, Marias C, Vecchio AD, Tenore G, Palaia G, et al.
Observation of pain control in patients with bisphosphonate-induced
osteonecrosis using low level laser therapy: preliminary results. Photomed
Laser Surg. 2011;29:447-52. |
|
|
|
|
|
13.
Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, et al.
Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated
osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser
Surg. 2008;26:37-46. |
|
|
|
|
|
14.
Monteiro L, Ferreira R, Resende T, Pacheco JJ, Salazar F. Effectiveness of
Photobiomodulation in Temporomandibular Disorder-Related Pain Using a 635 nm
Diode Laser: A Randomized, Blinded, and Placebo-Controlled Clinical Trial.
Photobiomodul Photomed Laser Surg. 2020;38:280-8. |
|
|
|
|
|
15.
Patil V, Acharya S, Vineetha R, Nikhil K. Awareness About Medication-Related
Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study.
Oral Health Prev Dent. 2020;18:505-9. PMid:32016175 |
|